1. Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma.
- Author
-
Moon SH, Lee AY, Kim WS, Kim SJ, Cho YS, Choe YS, Kim BT, and Lee KH
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Female, Humans, Image Processing, Computer-Assisted, Kaplan-Meier Estimate, Lymphoma, T-Cell drug therapy, Male, Middle Aged, Neoplasm Staging, Patient Outcome Assessment, Prednisone therapeutic use, Prognosis, Vincristine therapeutic use, Fluorodeoxyglucose F18, Immunoblastic Lymphadenopathy diagnostic imaging, Immunoblastic Lymphadenopathy pathology, Lymphoma, T-Cell diagnosis, Lymphoma, T-Cell mortality, Neovascularization, Pathologic pathology, Positron Emission Tomography Computed Tomography
- Abstract
Subjects were 45 patients with angioimmunoblastic T-cell lymphoma (AITL) who underwent 2-[
18 F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) at baseline and interim after 2-4 cycles. Predictors of progression-free survival (PFS) and overall survival (OS) were assessed. Positive interim PET/CT (Deauville score ≥3) was a significant independent predictor of poor PFS (Hazard ratio, 4.42; p=.028), and showed marginal significance to predict OS (p=.065). Less than 60% decrease in the average change of maximum standardized uptake value normalized by lean body mass (SULmax ) also was a significant independent predictor of poor PFS (Hazard ratio, 12.96; p=.001) and poor OS (Hazard ratio, 24.11; p=.006). Interim PET/CT has a significant prognostic value for predicting PFS and OS in patients with AITL. Deauville score and percent decrease of SULmax have the potential to be useful parameter in classifying patients into good and poor responders.- Published
- 2017
- Full Text
- View/download PDF